Future trends in drugs for migraine prophylaxis

Research output: Contribution to journalArticlepeer-review


Migraine prevention hinges on a variety of non-specific drugs that mainly reduce neuronal hyperexcitability, the putative pathophysiological hallmark for migraine. The improved knowledge about migraine circuitry and neurobiology has prompted research to develop new specific migraine preventive medications targeted to innovative sites and mechanisms. Drugs designed to inhibit cortical spreading depression, for example tonabersat, might offer a useful option for the management of migraine with aura but not for migraine without aura. Inducible nitric-oxide synthase (iNOS) inhibition seems ineffective as a prophylactic strategy. Results are awaited from recent and ongoing phase II trials with glutamate receptor antagonists, third-generation antiepileptics, melatonin agonists, vitamin D3 and statins.

Original languageEnglish
JournalNeurological Sciences
Issue numberSUPPL. 1
Publication statusPublished - May 2012


  • Disability
  • Migraine
  • Prophylaxis
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology


Dive into the research topics of 'Future trends in drugs for migraine prophylaxis'. Together they form a unique fingerprint.

Cite this